Kintara Therapeutics Alpha and Beta Analysis
| KTRADelisted Stock | USD 6.30 0.14 2.17% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Kintara Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Kintara Therapeutics over a specified time horizon. Remember, high Kintara Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Kintara Therapeutics' market risk premium analysis include:
Beta 0.18 | Alpha (0.44) | Risk 7.72 | Sharpe Ratio 0.0512 | Expected Return 0.4 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Kintara |
Kintara Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Kintara Therapeutics market risk premium is the additional return an investor will receive from holding Kintara Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Kintara Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Kintara Therapeutics' performance over market.| α | -0.44 | β | 0.18 |
Kintara Therapeutics Fundamentals Vs Peers
Comparing Kintara Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Kintara Therapeutics' direct or indirect competition across all of the common fundamentals between Kintara Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Kintara Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Kintara Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Kintara Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Kintara Therapeutics to competition |
| Fundamentals | Kintara Therapeutics | Peer Average |
| Return On Equity | -3.71 | -0.31 |
| Return On Asset | -1.04 | -0.14 |
| Current Valuation | 17.98 M | 16.62 B |
| Shares Outstanding | 55.66 M | 571.82 M |
| Shares Owned By Insiders | 0.12 % | 10.09 % |
| Shares Owned By Institutions | 1.47 % | 39.21 % |
| Number Of Shares Shorted | 5.43 M | 4.71 M |
Kintara Therapeutics Opportunities
Kintara Therapeutics Return and Market Media
The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc. | 09/09/2024 |
2 | Tetra Pharm Technologies Relocates to Copenhagen Towers | 09/18/2024 |
3 | Amphastar Pharm Sees Composite Rating Climb To 97 | 09/19/2024 |
4 | Kintara Therapeutics modifies merger terms with TuHURA Biosciences - Investing.com India | 09/26/2024 |
5 | Individual investors who hold 55 percent of Hainan Poly Pharm. Co., Ltd gained 29, insiders profited as well | 10/04/2024 |
6 | Innovent and Ask Pharm Announce Strategic Collaboration for Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer | 10/08/2024 |
7 | IBD Rating Upgrades Amphastar Pharm Flashes Improved Relative Price Strength | 10/15/2024 |
8 | Amphastar Pharm Joins Elite List Of Stocks With 95-Plus Composite Rating | 10/17/2024 |
About Kintara Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Kintara or other delisted stocks. Alpha measures the amount that position in Kintara Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Kintara Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Kintara Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kintara Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Kintara Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Kintara Therapeutics. Please utilize our Beneish M Score to check the likelihood of Kintara Therapeutics' management manipulating its earnings.
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 16th of September 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of June 2023 Last Financial Announcement | View |
Build Portfolio with Kintara Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Kintara Stock
If you are still planning to invest in Kintara Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kintara Therapeutics' history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |